ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 561,13
1,09%
Dow Jones
39 169,52
0,13%
DAX
18 290,66
0,31%
Brent Oil
86,685
0,18%
Bitcoin
63 122,07
0,43%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Lixte Biotechnology Holdings Inc (LIXTW)

  7. Lixte Biotechnology Holdings Inc (LIXTW) Actualités

LIXTW

Lixte Biotechnology (LIXTW)

Lixte Biotechnology Holdings Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:LIXTW
DateHeureSourceTitreSymboleSociété
14/06/202420h47Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTWLixte Biotechnology Holdings Inc
14/06/202417h00GlobeNewswire Inc.LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical TrialNASDAQ:LIXTWLixte Biotechnology Holdings Inc
14/06/202415h30GlobeNewswire Inc.LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical TrialNASDAQ:LIXTWLixte Biotechnology Holdings Inc
06/06/202414h30GlobeNewswire Inc.Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune SystemNASDAQ:LIXTWLixte Biotechnology Holdings Inc
03/06/202414h30GlobeNewswire Inc.LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical OfficerNASDAQ:LIXTWLixte Biotechnology Holdings Inc
09/05/202414h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LIXTWLixte Biotechnology Holdings Inc
08/05/202415h25GlobeNewswire Inc.LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”NASDAQ:LIXTWLixte Biotechnology Holdings Inc
24/04/202421h25AllPennyStocks.comMixed Shelf Filing Gives Micro Cap Delayed BoostNASDAQ:LIXTWLixte Biotechnology Holdings Inc
27/03/202420h35AllPennyStocks.comBiotech Steals The Show Following Pre-Clinical Data AnnouncementNASDAQ:LIXTWLixte Biotechnology Holdings Inc
27/03/202413h30GlobeNewswire Inc.NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIESNASDAQ:LIXTWLixte Biotechnology Holdings Inc
21/03/202413h30GlobeNewswire Inc.LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer TreatmentsNASDAQ:LIXTWLixte Biotechnology Holdings Inc
27/02/202414h30GlobeNewswire Inc.Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer ResearchNASDAQ:LIXTWLixte Biotechnology Holdings Inc
26/02/202414h30GlobeNewswire Inc.LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCINASDAQ:LIXTWLixte Biotechnology Holdings Inc
29/01/202414h30GlobeNewswire Inc.First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma TrialNASDAQ:LIXTWLixte Biotechnology Holdings Inc
13/11/202314h30GlobeNewswire Inc.LIXTE Biotechnology Provides Update on Clinical Progress and Expanding CollaborationsNASDAQ:LIXTWLixte Biotechnology Holdings Inc
16/10/202314h30GlobeNewswire Inc.LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand CollaborationNASDAQ:LIXTWLixte Biotechnology Holdings Inc
09/10/202314h30GlobeNewswire Inc.LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. KovachNASDAQ:LIXTWLixte Biotechnology Holdings Inc
26/09/202314h30GlobeNewswire Inc.LIXTE Appoints Bas van der Baan as President and Chief Executive OfficerNASDAQ:LIXTWLixte Biotechnology Holdings Inc
20/09/202314h30GlobeNewswire Inc.LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian CancerNASDAQ:LIXTWLixte Biotechnology Holdings Inc
20/07/202322h05GlobeNewswire Inc.LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq RulesNASDAQ:LIXTWLixte Biotechnology Holdings Inc
18/07/202314h00GlobeNewswire Inc.LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq RulesNASDAQ:LIXTWLixte Biotechnology Holdings Inc
17/07/202314h30GlobeNewswire Inc.Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and ChemotherapyNASDAQ:LIXTWLixte Biotechnology Holdings Inc
01/12/202018h30GlobeNewswire Inc.Lixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to NasdaqNASDAQ:LIXTWLixte Biotechnology Holdings Inc
30/11/202021h52Business WireWestPark Capital Announces Closing of $5,700,000 Follow-On Offering & NASDAQ Up-listing of Lixte Biotechnology Holdings, Inc....NASDAQ:LIXTWLixte Biotechnology Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:LIXTW

Dernières Valeurs Consultées

EU
BNP
BNP Paribas
EU
RNO
Renault
EU
LR
Legrand
EU
PX1
CAC 40
EU
AF
Air FranceKLM
EU
ML
Michelin
NYSE
KO
Coca Cola
SPI
SP500
S&P 500
EU
DG
Vinci
NASDAQ
AMZN
Amazon.com
EU
CS
Axa
COIN
ETHUSD
Ethereum
FTSE
UKX
FTSE 100
NYSE
MRK
Merck
EU
CAP
Capgemini
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés